Rare Diseases
News
Budesonide tablets considerably outperformed placebo for active EoE
After 6 weeks, 34 of 59 patients (58%) receiving budesonide orodispersible tablets had achieved complete remission.
Conference Coverage
R2 appears active in high-risk FL and MZL
CHICAGO – R2 produced responses in patients who were refractory to rituximab or both lenalidomide and rituximab at baseline.
Latest News
New tickborne virus emerges in China
A previously unknown RNA segmented virus was associated with a febrile illness that spread to 86 patients.
News
Do You Know Rocky Mountain Spotted Fever When You See It?
The rates of the most severe form of spotted fever rickettsiosis is on the rise, but are health care providers able to recognize it enough to...
News
Pexidartinib gets ODAC nod for tenosynovial giant cell tumor treatment
Missing efficacy data from the pivotal ENLIVEN trial and adverse liver events were points of contention.
Conference Coverage
Baseline imaging recommended in all Merkel cell carcinoma patients
CHICAGO – New data emphasize the need for routine baseline scans in patients with Merkel cell carcinoma.
Conference Coverage
Researchers propose new risk groups for NK-AML
NEWPORT BEACH, CALIF. – Investigators used machine learning algorithms to risk stratify patients with normal karyotype acute myeloid leukemia.
News
FDA approves ivosidenib frontline for certain AML patients
The expanded approval means that ivosidenib can be used first-line for acute myeloid leukemia patients with an IDH1 mutation who are not eligible...
News
Idelalisib shows long-term safety, efficacy for relapsed CLL
The long-term data confirm that the addition of idelalisib to rituximab significantly improves outcomes for patients with relapsed CLL. However,...
Conference Coverage
Three-drug regimen shows promise for refractory primary biliary cholangitis
VIENNA – Combining ursodeoxycholic acid, obeticholic acid, and bezafibrate showed efficacy and tolerability for the toughest cases.